International union of basic and clinical pharmacology. CII: Pharmacological modulation of H₂S levels: H₂s donors and H₂S biosynthesis inhibitors

Keyphrases

• Non-steroidal Anti-inflammatory Drugs (NSAIDs) 100%
• Clinical Pharmacology 100%
• Pharmacological Modulation 100%
• H2S Donors 100%
• Basic Pharmacology 100%
• Biosynthesis Inhibitor 100%
• Gasotransmitter 100%
• International Unions 100%
• Aging 50%
• Inflammation 50%
• Cell Permeable 50%
• Multiple Approaches 50%
• Clinical Trials 50%
• Inhalation 50%
• Ischemia 50%
• Pharmacological Inhibitors 50%
• Nitric Oxide 50%
• Type 1 Diabetes Mellitus (T1DM) 50%
• Mammalian Cells 50%
• Carbon Dioxide 50%
• Potential Therapeutics 50%
• Genetic Approach 50%
• Prodrug 50%
• Pathophysiological Processes 50%
• Mammalian Tissue 50%
• Hydrogen Sulfide 50%
• Cystathionine Synthase 50%
• Mode of Action 50%
• Critical Illness 50%
• H2S-producing Enzymes 50%
• 3-mercaptopyruvate Sulfurtransferase 50%
• Small Molecule Compounds 50%
• Parenteral Administration 50%
• Endogenous H2S 50%
• Cystathionine Lyase 50%
• H2S Gas 50%
• Sodium Hydrosulfide 50%
• PH Dependence 50%
• Physiological Processes 50%
• Naproxen 50%
• Organelle Targeting 50%
• Biologic Processes 50%
• Na2S 50%
• H2S Production 50%
• Esterase 50%
• Therapeutic Utility 50%
• Clinical Translation 50%
• Enteral Administration 50%
• Biologic Effect 50%
• Release Profile 50%
• Enzymatic Reaction 50%
• H2S Release 50%
• GYY4137 50%
• ATB-346 50%
• Benserazide 50%
• Aminooxyacetate 50%
• Clinically Approved Drugs 50%

Medicine and Dentistry

• Cystathionine 100%
• Anti-Inflammatory Drug 100%
• Gasotransmitter 100%
• Malignant Neoplasm 50%
• Clinical Trial 50%
• In Vitro 50%
• Synthetase 50%
• Nitric Oxide 50%
• Diabetes Mellitus 50%
• Carbon Monoxide 50%
• Oxidizing Agent 50%
• Ischemia 50%
• Hydrogen Sulfide 50%
• Aminooxyacetic Acid 50%
• Critical Illness 50%
• Biological Product 50%
• Parenteral Drug Administration 50%
• Lyase 50%
• Mammalian Cell 50%
• 3 Mercaptopyruvate Sulfurtransferase 50%
• Enteral Administration 50%
• Naproxen 50%
• Prodrug 50%
• Esterase 50%
• Benserazide 50%
• Biological Activity 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Anti-Inflammatory Drug 100%
• Clinical Pharmacology 100%
• Cystathionine 100%
• Gasotransmitter 100%
• Clinical Trial 50%
• Malignant Neoplasm 50%
• Synthetase 50%
• Ischemia 50%
• Inflammation 50%
• Diabetes Mellitus 50%
• Nitric Oxide 50%
• Prodrug 50%
• Oxidizing Agent 50%
• Hydrogen Sulfide 50%
• Aminooxyacetic Acid 50%
• Critical Illness 50%
• Biological Product 50%
• Esterase 50%
• Lyase 50%
• Carbon Monoxide 50%
• 3 Mercaptopyruvate Sulfurtransferase 50%
• Enteral Administration 50%
• Naproxen 50%
• Benserazide 50%